A Phase I Clinical Trial of JH013 Injection

Inclusion Criteria: * Healthy adult male or female aged 18-55 years (age including cut-off values); * There were no abnormalities in clinically significant vital signs, physical examination, laboratory tests, and 12-lead ECG; * Weight ≥ 50 kg for males and ≥45 kg for females; Body mass index (BMI) between 18.0 and 26 kg/m2 (including cut-off values, body mass index = weight/height2); * Females of potential childbearing potential with a negative blood β-HCG test within 72 hours prior to dosing (postmenopausal women who have amenorrhea for at least 12 months are considered non-childbearing and women who are known to have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or ligation, and a pregnancy test is not required); * Subjects understand and comply with the study process, participate voluntarily, and sign the informed consent form Exclusion Criteria: * Subject has a history of malignancy prior to screening, or has been screened for malignancy, and the possibility of malignancy cannot be reasonably ruled out * Subject has a history of autoimmune disease prior to screening * γ interferon release assay results ≥ 2 times the upper limit of normal * Any history of infection requiring hospitalization or receiving antivirals, antibiotics, antifungals, antiparasitic drugs, or vaccinations within 4 weeks prior to the application of the study drug * Those who have positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B virus (HBV)…